Lead Product(s) : Cantrixil
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Lonza Group
Deal Size : Undisclosed
Deal Type : Agreement
Oasmia Signs Manufacturing Agreement with Lonza for Ovarian Cancer Drug Candidate Cantrixil
Details : Under the terms of agreement, Lonza will provide kilogram-scale synthesis, purification, and stability testing of Cantrixil, and deliver cGMP batches of drug substance for clinical supply. Oasmia will leverage Lonza’s extensive experience in manufactur...
Brand Name : TRX-E-002-1
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 21, 2022
Lead Product(s) : Cantrixil
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Lonza Group
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Cantrixil
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Oasmia Pharmaceutical
Deal Size : $46.0 million
Deal Type : Licensing Agreement
Details : Oasmia will assume worldwide exclusive rights to develop and commercialise Cantrixil for all indications, with an initial focus on ovarian cancer.
Brand Name : TRE-E-002-1
Molecule Type : Small molecule
Upfront Cash : $4.0 million
March 01, 2021
Lead Product(s) : Cantrixil
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Oasmia Pharmaceutical
Deal Size : $46.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
